Who
Erick Lucera
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Dyne Therapeutics; Director, SAB Biotherapeutics; Director, Beyond Air; EVP, Chief Financial Officer, Editas Medicine; Director, Bone Biologics; Chief Financial Officer, Aveo Pharmaceuticals; Chief Financial Officer, Valeritas Holdings.
In numbers
- Trades disclosed
- 87
- Buys
- 4
- Sells
- 6
- Bought
- $67K
- Sold
- $590K
- Companies
- 7
- Companies where not an officer
- 3
- First trade
- 23 Mar 2017
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $47K1,797 at $26.28 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $47K1,797 at $26.28 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K2,362 at $20.37 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K2,362 at $20.37 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $27K1,448 at $18.36 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $27K1,448 at $18.36 | filing |
| 1 Apr 2026filed 3 Apr 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K5,727 at $18.64 | filing |
| 1 Apr 2026filed 3 Apr 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K5,727 at $18.64 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 4 Nov 2025filed 6 Nov 2025 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —2,250 | filing |
| 4 Nov 2025filed 6 Nov 2025 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,250 | filing |
| 4 Nov 2025filed 6 Nov 2025 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —2,000 | filing |
| 4 Nov 2025filed 6 Nov 2025 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,000 | filing |
| 4 Nov 2025filed 6 Nov 2025 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —1,500 | filing |
| 4 Nov 2025filed 6 Nov 2025 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —1,500 | filing |
| 4 Nov 2025filed 6 Nov 2025 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —1,250 | filing |
News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)DYN · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Erick Lucera; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.